The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Subscribe To Our Newsletter & Stay Updated
